Nabil F. Saba, MD, FACP

Articles

Dr Saba on Findings from the CONTINUUM Trial of Sintilimab in Nasopharyngeal Cancer

June 20th 2023

Nabil F. Saba, MD, FACP, discusses key findings from the phase 3 CONTINUUM trial of sintilimab plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.

A Look Towards the Future of ESCC

February 6th 2023

Closing out their conversation, Drs Saba and Yoon share their hopes for the future of ESCC, including elucidating the molecular mechanisms behind immune evasion and treatment response to chemotherapy, radiation, and immunotherapy.

Other Emerging Regimens in ESCC and Lessons from Other Squamous Cell Cancers

January 30th 2023

A review of other ongoing trials and emerging treatment regimens in the space and a summary of takeaways from trials on other squamous cell cancers that may also be applied to ESCC.

The Potential Impact of Tislelizumab on First-Line ESCC Treatment

January 30th 2023

Drs Saba and Yoon reflect on how the potential FDA approval and availability of tislelizumab might change first-line ESCC treatment paradigms in the future.

RATIONALE-306 Data on Tislelizumab in ESCC

January 25th 2023

Dr Yoon introduces tislelizumab, an anti-PD-1 immunotherapy regimen being investigated as a first-line ESCC treatment option in combination with chemotherapy, and discusses recent conference data from the RATIONALE-306 trial.

Insights on ESCC First-Line Treatment Selection

January 25th 2023

Drs Saba and Yoon share the factors they consider when choosing among available first-line regimens for ESCC, including clinical trial data and the patient’s PD-L1 expression status.

First-Line Options for Advanced/Metastatic Disease

January 16th 2023

A focused discussion on the available first-line treatment options for advanced/metastatic ESCC.

The Impact of Biomarker Results on Prognosis and Treatment Decision-Making

January 16th 2023

Drs Saba and Yoon share how a patient’s biomarker testing results typically affect prognosis and how they may influence subsequent treatment decision-making.

Approaches to Biomarker Testing for ESCC

December 21st 2022

Expert perspectives on the process of biomarker testing, including PD-L1 testing, for patients with unresectable locally advanced or metastatic ESCC.

Trends in ESCC Incidence and Observations from Clinical Practice

December 21st 2022

Nabil Saba, MD, FACP and Harry Yoon, MD, briefly review the incidence of esophageal squamous cell carcinoma (ESCC), and describe how many patients present with unresectable locally advanced or metastatic disease in their clinical practice.

Dr. Saba on the Investigation of Pembrolizumab Plus Cabozantinib in HNSCC

November 2nd 2022

Nabil Saba, MD, FACP, discusses the evaluation of pembrolizumab plus cabozantinib in patients with recurrent metastatic head and neck squamous cell carcinoma.

Dr. Saba on Disparities of Clinical Trials in Head and Neck Cancer

October 6th 2022

Nabil Saba, MD, FACP, discusses the disparities seen in clinical trials in head and neck cancer.

Dr. Saba on Unique Characteristics of Nasopharyngeal Carcinoma

April 15th 2021

Nabil F. Saba, MD, FACP, discusses some of the unique characteristics of nasopharyngeal carcinoma.

Dr. Saba Discusses Ongoing Trials in Head and Neck Cancer

November 12th 2020

Nabil F. Saba, MD, FACP, discusses ongoing clinical trials in head and neck cancer.

Dr. Saba on Scheduling Challenges With Cisplatin in Head and Neck Cancer

August 24th 2020

Nabil F. Saba, MD, FACP, discusses scheduling challenges with cisplatin in head and neck cancer.

Dr. Saba on Emerging Sequencing Strategies in Head and Neck Cancer

August 19th 2020

Nabil F. Saba, MD, FACP, discusses emerging sequencing strategies in head and neck cancer.

Dr. Saba on the Future of Treatment in Head and Neck Cancer

June 24th 2020

Nabil F. Saba, MD, FACP, discusses the future of treatment in head and neck cancer.

Dr. Saba on the Impact of COVID-19 on Telehealth in Head and Neck Cancer

May 4th 2020

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses the impact of the coronavirus disease 2019 (COVID-19) on telehealth in head and neck cancer.

Dr. Saba on Immunotherapy/Radiation Combo in Head and Neck Cancer

October 31st 2019

Nabil F. Saba, MD, FACP, discusses the potential benefit of immunotherapy in combination with radiation in head and neck cancer.

Dr. Saba on Anticipated Research in Head and Neck Cancer

October 31st 2019

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, and professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses anticipated research in head and neck cancer.